RxDoctor Payments Data

Jennifer Holloway, MD

Internal Medicine · Newtown, CTNPI 1285601898

Payments from drug & device makers

$21,818in general payments, 2019–2025

Across 1,099 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$3K
  • GSK$2K
  • Novo Nordisk$999
  • Boehringer Ingelheim$957
  • Takeda Pharmaceuticals U.S.A., Inc.$827
  • plus $10K from 51 others

What the payments were for

  • Food & beverage$21,710100%
  • Education$1080%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)251$4,285
AstraZeneca(2 entities)115$2,658
GSK75$1,664
Novo Nordisk47$999
Boehringer Ingelheim41$957
Takeda Pharmaceuticals U.S.A., Inc.51$827
Pfizer39$757
Otsuka America Pharmaceutical, Inc.30$688
Bayer33$673
Sanofi-aventis U.S. LLC29$636
Amgen35$614
Exact Sciences24$584
Lundbeck LLC21$531
Amarin Pharma, Inc.28$509
Lilly USA, LLC24$463
Johnson & Johnson(2 entities)27$457
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$450
Merck24$422
Astellas Pharma US Inc14$357
Esperion Therapeutics, Inc.13$281
Novartis13$265
Mylan Specialty L.p.13$263
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$249
E.r. Squibb & Sons, L.L.C.23$244
Phathom Pharmaceuticals, Inc.7$243
Optinose US, Inc.12$234
Biohaven Pharmaceutical Holding Company Ltd.8$154
Amneal Pharmaceuticals LLC7$144
Axsome Therapeutics, Inc.5$123
Sumitomo Pharma America, Inc.4$101
Impel Pharmaceuticals Inc.4$92
Medtronic(2 entities)4$81
Ironwood Pharmaceuticals, Inc3$72
Biohaven Pharmaceuticals, Inc.2$63
Corcept Therapeutics3$58
Idorsia Pharmaceuticals US Inc3$58
Eisai Inc.3$56
Neurocrine Biosciences, Inc.2$55
Daiichi Sankyo Inc.2$52
Ultragenyx Pharmaceutical Inc.2$36
Arbor Pharmaceuticals, Inc.2$35
Baxter Healthcare1$35
Viatris Specialty LLC2$34
Mayne Pharma Commercial LLC1$31
Bausch Health US, LLC2$28
Therapeuticsmd, Inc.1$24
Xeris Pharmaceuticals, Inc.1$24
Collegium Pharmaceutical, Inc.1$21
Otsuka Pharmaceutical Development & Commercialization, Inc.1$18
Almatica Pharma LLC1$17
Intra-sana Laboratories1$17
Sanofi Pasteur Inc.1$15
Vistapharm, Inc.1$15
Watermark Medical, Inc.1$15
Currax Pharmaceuticals LLC1$15
Genentech USA, Inc.1$12
Organon1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,818 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$162,401
Medicare patients
424
Services billed
2,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$115,478
JardianceEmpagliflozin69$87,868
XareltoRivaroxaban50$72,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$39,251
MyrbetriqMirabegron35$35,937
OxycontinOxycodone Hcl30$30,491
OzempicSemaglutide23$24,473
JanuviaSitagliptin Phosphate13$18,307
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$14,514
DuleraMometasone/Formoterol12$8,845
Breo ElliptaFluticasone/Vilanterol16$7,925
Atorvastatin Calcium707$6,414
SynthroidLevothyroxine Sodium68$6,412
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$5,240
Levothyroxine Sodium467$5,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$757$115,478103 claims
Boehringer IngelheimJardiance$957$87,86869 claims
Johnson & JohnsonXarelto$457$72,29350 claims
GSKTrelegy Ellipta, Breo Ellipta$1,664$47,17751 claims
Astellas Pharma US IncMyrbetriq$357$35,93735 claims
MerckJanuvia, Dulera$422$27,15225 claims
Novo NordiskOzempic$999$24,47323 claims
AbbVieSynthroid$4,285$6,41268 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$144$5,024467 claims
AstraZenecaSymbicort$2,658$4,18113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Newtown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →